Pharmaxis to cut jobs, spending

Company News

Pharmaxis Limited (ASX:PXS) says it will slash costs and focus on partnering strategies after completing a business review.
 
The pharmaceutical company says it will cut expenditure by almost 30 per cent, including extensive job losses and consolidation of manufacturing facilities.
 
Phamaxis says it has also begun talks with a number of third parties to secure funding for all or some of the company’s pipeline of early stage compounds.
 
The company plans to seek partnership opportunities for Bronchitol in the US while retaining a direct commercial interest in Bronchitol Europe.
 
CEO Gary Phillips says the strategy is aimed at mitigating some of the risks associated with drug development in the short term while focusing on long term returns.
 
Pharmaxis posted a net loss of $20.7 million in the first half of the current financial year.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.